AU2024276929A1 - Use of structure for nucleic acid delivery in treatment of hematopoietic tumor - Google Patents

Use of structure for nucleic acid delivery in treatment of hematopoietic tumor

Info

Publication number
AU2024276929A1
AU2024276929A1 AU2024276929A AU2024276929A AU2024276929A1 AU 2024276929 A1 AU2024276929 A1 AU 2024276929A1 AU 2024276929 A AU2024276929 A AU 2024276929A AU 2024276929 A AU2024276929 A AU 2024276929A AU 2024276929 A1 AU2024276929 A1 AU 2024276929A1
Authority
AU
Australia
Prior art keywords
nucleic acid
strand
cationic
rion
mir143
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024276929A
Other languages
English (en)
Inventor
Yukihiro Akao
Yukio Kitade
Noriko Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Japan Science and Technology Agency
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Science and Technology Agency filed Critical Japan Science and Technology Agency
Publication of AU2024276929A1 publication Critical patent/AU2024276929A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2024276929A 2023-05-19 2024-05-17 Use of structure for nucleic acid delivery in treatment of hematopoietic tumor Pending AU2024276929A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2023082728 2023-05-19
JP2023-082728 2023-05-19
PCT/JP2024/018410 WO2024242065A1 (ja) 2023-05-19 2024-05-17 核酸送達用構造体の造血器腫瘍の治療への使用

Publications (1)

Publication Number Publication Date
AU2024276929A1 true AU2024276929A1 (en) 2025-12-18

Family

ID=93589879

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024276929A Pending AU2024276929A1 (en) 2023-05-19 2024-05-17 Use of structure for nucleic acid delivery in treatment of hematopoietic tumor

Country Status (5)

Country Link
EP (1) EP4714453A1 (https=)
JP (1) JP7725042B2 (https=)
CN (1) CN121175056A (https=)
AU (1) AU2024276929A1 (https=)
WO (1) WO2024242065A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10487103B2 (en) 2015-03-24 2019-11-26 Gifu University Oligonucleotide derivative, oligonucleotide construct using the same, and methods for producing them
WO2017179660A1 (ja) 2016-04-14 2017-10-19 国立大学法人岐阜大学 マイクロｒｎａ－１４３誘導体
US20240238325A1 (en) 2021-04-28 2024-07-18 Japan Science And Technology Agency Artificial Nucleic Acid and Method for Delivery of Nucleic Acid Using the Same

Also Published As

Publication number Publication date
JP7725042B2 (ja) 2025-08-19
EP4714453A1 (en) 2026-03-25
WO2024242065A1 (ja) 2024-11-28
CN121175056A (zh) 2025-12-19
JPWO2024242065A1 (https=) 2024-11-28

Similar Documents

Publication Publication Date Title
EP2264167B1 (en) Double-stranded lipid-modified rna having high rna interference effect
SG185295A1 (en) Lipid-modified double-stranded rna having potent rna interference effect
KR20180039621A (ko) 정의된 다중 접합체 올리고뉴클레오티드
EP3858846A1 (en) Nucleic acid nanocarrier medicament, preparation method therefor, pharmaceutical composition thereof, and use thereof
EP4331617A1 (en) Artificial nucleic acid and nucleic acid delivering method using same
JP6492014B2 (ja) 遺伝子発現制御のための人工マッチ型ｍｉＲＮＡおよびその用途
AU2024276929A1 (en) Use of structure for nucleic acid delivery in treatment of hematopoietic tumor
CN111150852B (zh) 含顺铂的药物、其制备方法、药物组合物及其应用
CN110960683B (zh) 含甲氨蝶呤的药物、其制备方法、药物组合物及其应用
CN111096965B (zh) 含双氢青蒿素的药物、其制备方法、药物组合物及其应用
CN110960530B (zh) 含他克林的药物、其制备方法、药物组合物及其应用
CN110960534B (zh) 含五氟尿嘧啶的药物、其制备方法、药物组合物及其应用
CN111053765B (zh) 含紫杉醇的药物、其制备方法、药物组合物及应用
CN111053913B (zh) 含阿糖胞苷的药物、其制备方法、药物组合物及应用
CN110960691B (zh) 含吉西他滨的药物、其制备方法、药物组合物及应用
CN110960542B (zh) 含吡柔比星的药物、其制备方法、药物组合物及其应用
CN111053914B (zh) 含米托蒽醌的药物、其制备方法、药物组合物及其应用
CN110960689B (zh) 含柔红霉素的药物、其制备方法、药物组合物及其应用
CN110960684B (zh) 含10-羟基喜树碱的药物、其制备方法、药物组合物及其应用
CN110960690B (zh) 含表柔比星的药物、其制备方法、药物组合物及其应用
CN110960536B (zh) 含阿司匹林的药物、其制备方法、药物组合物及应用
CN111053919B (zh) 含伊达比星的药物、其制备方法、药物组合物及其应用
CN111166894B (zh) 含多西他赛的药物、其制备方法、药物组合物及应用
WO2025225509A1 (ja) 核酸送達用構造体、核酸送達用構造体の製造方法、及び医薬
Abdelaal Enhancing miRNA Therapeutics Using Ligand Conjugated and Chemically Modified Tumor Suppressive miRNAs